Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513) Stock Analysis

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 11.37% and Operating profit at -7.30% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 10.90% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 11.37% and Operating profit at -7.30% over the last 5 years

The company has declared negative results for the last 3 consecutive quarters

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 5,535 Million (Mid Cap)

P/E

4,022.00

Industry P/E

Dividend Yield

0.46%

Debt Equity

0.90

Return on Equity

0.10%

Price to Book

4.16

Revenue and Profits:

Net Sales:

652 Million

(Quarterly Results - Jun 2025)

Net Profit:

-60 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

87.37%

6 Months

69.95%

1 Year

118.6%

2 Years

84.13%

3 Years

65.6%

4 Years

94.83%

5 Years

69.48%

Jiangsu Lianhuan Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.37%

EBIT Growth (5y)

-7.30%

EBIT to Interest (avg)

7.49

Debt to EBITDA (avg)

2.74

Net Debt to Equity (avg)

0.70

Sales to Capital Employed (avg)

0.96

Tax Ratio

21.08%

Dividend Payout Ratio

30.19%

Pledged Shares

Institutional Holding

ROCE (avg)

9.67%

ROE (avg)

10.90%

Valuation key factors

Factor

Value

P/E Ratio

4022

Industry P/E

Price to Book Value

4.16

EV to EBIT

77.26

EV to EBITDA

41.68

EV to Capital Employed

2.67

EV to Sales

2.93

PEG Ratio

Dividend Yield

0.46%

ROCE (Latest)

3.45%

ROE (Latest)

0.10%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.17% vs 18.81% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -267.51% vs 9.51% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "652.10",
          "val2": "591.90",
          "chgp": "10.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "40.50",
          "val2": "64.30",
          "chgp": "-37.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.40",
          "val2": "6.80",
          "chgp": "23.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-59.80",
          "val2": "35.70",
          "chgp": "-267.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "29.10%",
          "val2": "82.70%",
          "chgp": "-5.36%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.63% vs 11.22% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -29.68% vs -9.07% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,140.70",
          "val2": "2,154.20",
          "chgp": "-0.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "182.30",
          "val2": "235.10",
          "chgp": "-22.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "25.20",
          "val2": "27.00",
          "chgp": "-6.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "106.40",
          "val2": "151.30",
          "chgp": "-29.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "56.20%",
          "val2": "82.20%",
          "chgp": "-2.60%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

652.10

591.90

10.17%

Operating Profit (PBDIT) excl Other Income

40.50

64.30

-37.01%

Interest

8.40

6.80

23.53%

Exceptional Items

0.00

Consolidate Net Profit

-59.80

35.70

-267.51%

Operating Profit Margin (Excl OI)

29.10%

82.70%

-5.36%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 10.17% vs 18.81% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -267.51% vs 9.51% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2,140.70

2,154.20

-0.63%

Operating Profit (PBDIT) excl Other Income

182.30

235.10

-22.46%

Interest

25.20

27.00

-6.67%

Exceptional Items

0.00

1.80

-100.00%

Consolidate Net Profit

106.40

151.30

-29.68%

Operating Profit Margin (Excl OI)

56.20%

82.20%

-2.60%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -0.63% vs 11.22% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -29.68% vs -9.07% in Dec 2023

All Annual Results

Company CV

About Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available